Merck company profile
Company profile
Merck has 61,949 employees and is headquartered in Darmstadt, Germany.
Revenue of EUR 21.1 billion comes from three segments that serve very different customers. Life Science supplies academic, research and diagnostic laboratories, biotech and pharmaceutical companies, and industrial clients with reagents, consumables, lab water instruments and flow cytometry kits, along with bioprocessing products such as chromatography resins and single-use systems, and contract development and manufacturing services. Healthcare develops and sells prescription drugs and biopharmaceuticals for oncology, rare diseases, neurology, immunology, fertility, cardiovascular and metabolic disorders. Electronics supplies semiconductor manufacturers with high-purity gases, photoresists and planarization materials, as well as liquid crystals and OLED materials. Sales are spread across Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific.
In the fiscal year ended December 31, 2025, revenue declined by 0.3% from the previous year, and net income reached EUR 2.6 billion. The group reports 61,949 employees. It traces its origins to 1668, has its headquarters in Darmstadt, Germany, and operates as a subsidiary of E. Merck KG.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Germany
- Headquarters
- Frankfurter Strasse 250, 64293, Darmstadt
- Employees
- 61,949
- Chief executive
- Kai Beckmann
- Founded
- 1668
- Fiscal year
- January - December
- Listing
- MRK · Xetra
- Indices
- DAX
- Currency
- EUR
- ISIN
- DE0006599905
- Website
- merckgroup.com
Merck and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| MerckMRK | Germany | $71.52B | 61,949 | 17.0% | 33.9 |
| Galderma GroupGALD | Switzerland | $51.94B | 7,676 | 19.1% | 64.5 |
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
